Drugs Made In America Acquisition II closes $500M IPO and $12M private placement

Drugs Made In America Acquisition II Corp.

IPO of 50M units at $10 each grossed $500M; units trade on Nasdaq (DMIIU).
Private placement of 1.2M units to sponsor and Cantor Fitzgerald raised $12M.
$500M deposited into trust account; company has 24 months to complete initial business combination.
Balance sheet: $1.58M cash, $17.5M deferred underwriting liability, $17.2M accumulated deficit.
Auditor includes going concern qualification due to mandatory liquidation if no business combination within 24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.